Form 4: Director Steven Loranger Increases Stake in Edwards Lifesciences
Statement of Changes in Beneficial Ownership
Director Steven R. Loranger acquired 4,315 restricted stock units in Edwards Lifesciences Corporation as part of the company's nonemployee director incentive program.
Summary
- Director Steven R. Loranger received a grant of 3,251 restricted stock units (RSUs) on May 8, 2026.
- Director Steven R. Loranger received an additional restricted stock award of 1,064 shares on May 8, 2026.
- The total direct beneficial ownership for the director increased to 8,997 shares following these transactions.
- The director maintains an additional indirect holding of 75,372 shares held in a trust.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral, routine regulatory disclosure regarding director compensation that does not signal a change in company strategy or financial health.
Positives
- Alignment of director interests with shareholders through equity-based compensation.
- Demonstrates long-term commitment from a member of the board of directors.
Negatives
- None identified; this is a standard equity grant for board service.
Risks
- None identified; this is a standard equity grant for board service.
Future Outlook
The granted securities are scheduled to vest 100% after the earlier of one year from the grant date or the issuer's next annual meeting of stockholders.
Industry Context
StockSavvy.ai notes that equity grants to non-employee directors are a standard corporate governance practice in the medical device industry to ensure board members have a vested interest in long-term company performance.
Comparison to Industry Standards
- The grant structure aligns with standard compensation practices for S&P 500 companies.
- Vesting schedules are consistent with typical annual director equity refresh cycles seen at peers like Medtronic or Boston Scientific.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation | Grant of equity under the 2020 Nonemployee Directors Stock Incentive Program. | 05/08/2026 | Standard alignment of director incentives with shareholder interests. |
Stakeholder Impact
- Positive signal for shareholders as it reflects director confidence and alignment.
Next Steps
- Vesting of the granted shares in May 2027 or upon the next annual meeting of stockholders.
Key Dates
| Date | Description |
|---|---|
| 05/08/2026 | Grant date of restricted stock units and restricted stock awards to Director Steven R. Loranger. |
Keywords
Edwards Lifesciences, EW, Insider Trading, Form 4, Director Compensation, Equity Grant
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.